Investor · 3 deals
Every published round Canaan Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Sumble | Series A | 24 Oct 2025 | $46m | Lead | Startup Daily, SmartCompany, Square Peg Capital portfolio | |
| World View | Series D+ | 15 May 2024 | $37m | Participant | SmartCompany, Startup Daily (15 Sep 2026), Startup Daily (4 Nov 2024), Startup Daily (19 Jun 2024), Startup Daily (16 May 2024), Breakthrough Victoria (16 May 2024), Breakthrough Victoria (3 May 2024), Breakthrough Victoria (3 May 2024) | |
| Spinifex Pharmaceuticals | Series C | 13 May 2014 | US$45m (A$48.3m) | Participant | bionity.com, GBS Ventures (30 Jun 2015), clinicalleader.com, GBS Ventures (13 May 2014) |
Companies Canaan Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | UQ spin-out sold to Novartis in 2015 | 13 May 2014, Series C | 1 | 0 |
| Sumble | Sales intelligence startup | 24 Oct 2025, Series A | 1 | 1 |
| World View | 15 May 2024, Series D+ | 1 | 0 |
Fund closes reported for Canaan Partners, as distinct from the investments it has made.
Companies Canaan Partners has backed that another company then bought. An exit for the holding, not a deal Canaan Partners did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | US$200m+ (A$260m+) |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | US$700m (A$911m) |
Stories naming Canaan Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of a quiet funding week: Melbourne workforce-platform maker 2cloudnine banked over $7.5m, algae-ingredient maker SeaStock $740,000 from government accelerator FaBA, while San Francisco's Sumble emerged with $59m.
Also Startup Daily
UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia
Pain-drug developer Spinifex Pharmaceuticals hires Dr Ronald Marcus as chief medical officer; CEO Tom McCarthy cites a recent $45 million raise backing further phase 2 trials of EMA401.